Management of prostate cancer in HIV-positive patients

Matthew S. Wosnitzer, Franklin C. Lowe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Improved medical therapy for HIV-positive patients has helped delay the progression of HIV to AIDS and reduce AIDS deaths. This dramatically prolonged survival has resulted in increased detection of non-AIDS-defining malignancies, such as prostate cancer, in people with HIV. Reported prostate cancer incidences in HIV-positive men compared with the general population vary in different studies; however, its incidence in the general population has generally increased over time, owing to the widespread use of PSA testing and increased life expectancy. In the highly active antiretroviral therapy (HAART) era, evidence indicates that PSA kinetics and prostate cancer behavior are similar in HIV-positive and HIV-negative patients. Current American Urological Association (AUA) guidelines recommend screening of all men aged ≥40 years with a life expectancy >10 years, and HIV-positive patients should be included in this recommendation. Treatment options for HIV-positive patients with prostate cancer should include all those offered to the general population. Long-term treatment outcomes in HIV-positive patients remain uncertain; however, early results suggest response rates similar to those in HIV-negative patients.

Original languageEnglish (US)
Pages (from-to)348-357
Number of pages10
JournalNature Reviews Urology
Volume7
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Prostatic Neoplasms
HIV
Life Expectancy
Acquired Immunodeficiency Syndrome
Population
Incidence
Highly Active Antiretroviral Therapy
Guidelines
Survival
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Management of prostate cancer in HIV-positive patients. / Wosnitzer, Matthew S.; Lowe, Franklin C.

In: Nature Reviews Urology, Vol. 7, No. 6, 06.2010, p. 348-357.

Research output: Contribution to journalArticle

Wosnitzer, Matthew S. ; Lowe, Franklin C. / Management of prostate cancer in HIV-positive patients. In: Nature Reviews Urology. 2010 ; Vol. 7, No. 6. pp. 348-357.
@article{a9f5858580e940aeb299f4fd97be9dbf,
title = "Management of prostate cancer in HIV-positive patients",
abstract = "Improved medical therapy for HIV-positive patients has helped delay the progression of HIV to AIDS and reduce AIDS deaths. This dramatically prolonged survival has resulted in increased detection of non-AIDS-defining malignancies, such as prostate cancer, in people with HIV. Reported prostate cancer incidences in HIV-positive men compared with the general population vary in different studies; however, its incidence in the general population has generally increased over time, owing to the widespread use of PSA testing and increased life expectancy. In the highly active antiretroviral therapy (HAART) era, evidence indicates that PSA kinetics and prostate cancer behavior are similar in HIV-positive and HIV-negative patients. Current American Urological Association (AUA) guidelines recommend screening of all men aged ≥40 years with a life expectancy >10 years, and HIV-positive patients should be included in this recommendation. Treatment options for HIV-positive patients with prostate cancer should include all those offered to the general population. Long-term treatment outcomes in HIV-positive patients remain uncertain; however, early results suggest response rates similar to those in HIV-negative patients.",
author = "Wosnitzer, {Matthew S.} and Lowe, {Franklin C.}",
year = "2010",
month = "6",
doi = "10.1038/nrurol.2010.61",
language = "English (US)",
volume = "7",
pages = "348--357",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Management of prostate cancer in HIV-positive patients

AU - Wosnitzer, Matthew S.

AU - Lowe, Franklin C.

PY - 2010/6

Y1 - 2010/6

N2 - Improved medical therapy for HIV-positive patients has helped delay the progression of HIV to AIDS and reduce AIDS deaths. This dramatically prolonged survival has resulted in increased detection of non-AIDS-defining malignancies, such as prostate cancer, in people with HIV. Reported prostate cancer incidences in HIV-positive men compared with the general population vary in different studies; however, its incidence in the general population has generally increased over time, owing to the widespread use of PSA testing and increased life expectancy. In the highly active antiretroviral therapy (HAART) era, evidence indicates that PSA kinetics and prostate cancer behavior are similar in HIV-positive and HIV-negative patients. Current American Urological Association (AUA) guidelines recommend screening of all men aged ≥40 years with a life expectancy >10 years, and HIV-positive patients should be included in this recommendation. Treatment options for HIV-positive patients with prostate cancer should include all those offered to the general population. Long-term treatment outcomes in HIV-positive patients remain uncertain; however, early results suggest response rates similar to those in HIV-negative patients.

AB - Improved medical therapy for HIV-positive patients has helped delay the progression of HIV to AIDS and reduce AIDS deaths. This dramatically prolonged survival has resulted in increased detection of non-AIDS-defining malignancies, such as prostate cancer, in people with HIV. Reported prostate cancer incidences in HIV-positive men compared with the general population vary in different studies; however, its incidence in the general population has generally increased over time, owing to the widespread use of PSA testing and increased life expectancy. In the highly active antiretroviral therapy (HAART) era, evidence indicates that PSA kinetics and prostate cancer behavior are similar in HIV-positive and HIV-negative patients. Current American Urological Association (AUA) guidelines recommend screening of all men aged ≥40 years with a life expectancy >10 years, and HIV-positive patients should be included in this recommendation. Treatment options for HIV-positive patients with prostate cancer should include all those offered to the general population. Long-term treatment outcomes in HIV-positive patients remain uncertain; however, early results suggest response rates similar to those in HIV-negative patients.

UR - http://www.scopus.com/inward/record.url?scp=77953617456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953617456&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2010.61

DO - 10.1038/nrurol.2010.61

M3 - Article

VL - 7

SP - 348

EP - 357

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 6

ER -